| Name | Title | Contact Details |
|---|
The Warner Babcock Institute for Green Chemistry is dedicated to the development of non toxic, environmentally benign and sustainable technological solutions for society. Focused on the practical application of Green Chemistry, we assist our industry partners in the development of sustainable technologies, products, and processes at the molecular level. Our emphasis is on the practical application of Green Chemistry concepts to drive cost savings and minimize time to market. The Warner Babcock Institute for Green Chemistry was founded in 2007 by Dr. John C. Warner, one of the founders of the field and co-author of seminal book Green Chemistry: Theory and Practice, which first defined the Twelve Principles of Green Chemistry.
Legacy Press is a Blackwood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RRS Ohio is a company that offers effective outpatient, individualized addiction treatment and substance abuse disorder treatment. They provide a neutral safe space for individuals to heal, energize, and become aware of their inner strengths.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Interwell Health is a kidney care management company that partners with physicians on its mission to reimagine healthcare – with the expertise, compassion, and vision to set the standard for the industry and help patients live their best lives. The company is differentiated by its ability to deliver improved clinical outcomes and better quality of life for patients, reduce the total cost of care for payer partners, and provide the resources physicians need to thrive in a value-based world – all at scale.